Keratoacanthoma
☆ AI Dermatology — Free Service
ໃນປີ 2022 Stiftung Warentest ຜົນໄດ້ຮັບຈາກເຢຍລະມັນ, ຄວາມພໍໃຈຂອງຜູ້ບໍລິໂພກກັບ ModelDerm ແມ່ນຕໍ່າກວ່າການປຶກສາຫາລືທາງດ້ານການປິ່ນປົວທາງໂທລະສັບເລັກນ້ອຍເທົ່ານັ້ນ.
ໃນປີ 2022 Stiftung Warentest ຜົນໄດ້ຮັບຈາກເຢຍລະມັນ, ຄວາມພໍໃຈຂອງຜູ້ບໍລິໂພກກັບ ModelDerm ແມ່ນຕໍ່າກວ່າການປຶກສາຫາລືທາງດ້ານການປິ່ນປົວທາງໂທລະສັບເລັກນ້ອຍເທົ່ານັ້ນ.
Keratoacanthoma (ທຳມະດາ)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) ເປັນໂຕແບບຂອງການຕັດຂອງຜິວໜັງທີ່ມີການເຕັ່ງໄວ ແລະ ມີຄວາມສາມາດກັບຄືນດ້ວຍຕົວມັນເອງ. ປົກກະຕິມັນພົບໃນຜູ້ຊາຍອາຍຸກາງ ແລະ ຜິວພັນທີ່ມີປະຫວັດການເສຍຫາຍຈາກແສງອົງການອາວຸດ. ການຜ່າຕັດທີ່ມີການຂັບເຄື່ອນດ້ວຍການຕັດອອກຫຼື Mohs micrographic ແມ່ນວິທີປິ່ນປົວທີ່ພົບບໍ່ກັນ, ແລະ ມີທາງເລືອກອື່ນໆ ສຳລັບການປິ່ນປົວ.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) ເປັນເນື້ອງອກລະດັບຕ່ຳ ທີ່ເລີ່ມຢູ່ໃນຕ່ອມບາງອັນໃນຜິວໜັງ ແລະມີລັກສະນະຄ້າຍກັບ squamous cell carcinoma (SCC) ພາຍໃຕ່ກ້ອງຈຸລະທັດ. ມີການໂຕ້ວາທີ່ຍັງຕໍ່ເນື່ອງກ່ຽວກັບວ່າ KA ຄວນຖືກຈັດໝາຍເປັນຮູບແບບຂອງ SCC ທີ່ຮຸກຮານ ຫຼື ບໍ່.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) ເປັນມະເຮັງຊະນິດທີ 2 ທີ່ພົບເລື້ອຍໃນຄົນ, ສະເພາະຜູ້ສູງອາຍຸ. ການຜ່າຕັດແມ່ນວິທີປົກກະຕິທີ່ໃຊ້ເພື່ອປິ່ນປົວ cSCC, ແຕ່ສໍາລັບຜູ່ເຈັບບາງຄົນທີ່ບໍ່ສາມາດຜ່າຕັດ ຫຼື ເລືອກວິທີອື່ນ, ການປິ່ນປົວ intralesional ສາມາດເປັນທາງເລືອກ. ວິທີປິ່ນປົວ intralesional ດ້ວຍ methotrexate ຫຼື 5‑fluorouracil ໄດ້ຖືກນໍາໃຊ້ແລ້ວ, ແຕ່ຍັງມີການຄົ້ນຄວ້າຕໍ່ເນື່ອງກ່ຽວກັບວິທີການໃໝ່ເຊັ່ນ immunotherapy intralesional ແລະ virotherapy oncolytic. ໃນບົດຄັດສະແດງນີ້, ພວກເຮົາຈະສະແດງວິທີປິ່ນປົວ intralesional ທີ່ແຕກຕ່າງກັນສໍາລັບ cSCC, ຈາກການປິ່ນປົວດ້ວຍການຄລາສສິກ (cryosurgery) ຫາກ່ອນເຖິງການປິ່ນປົວທີ່ທັນສະໄໝທີ່ມີປະສິດທິຜົນສູງ.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
ພາຍໃຕ້ກ້ອງຈຸລະທັດ, Keratoacanthoma ຄ້າຍຄືກັນກັບມะເຮັງຈຸລັງ squamous. ໃນຂະນດທີ່ນັກວິນິດໄສບາງຄົນຈັດປະເພດ Keratoacanthoma ເປັນຫົວໜ່ວຍທີ່ແຕກຕ່າງ ແລະບໍ່ແມ່ນພະຍາດມะເຮັງ, ປະມານ 6% ຂອງການຄລິນິກ ແລະ ຊີວະວິທະຍາ Keratoacanthoma ກ້າວໄປສູ່ມะເຮັງຈຸລັງ squamous ທີ່ຮຸກຮານ ແລະ ຮຸກຮານ.
○ ວິນິດໄສ ແລະການປິ່ນປົວ
#Dermoscopy
#Skin biopsy